Literature DB >> 27222715

MALDI-TOF MS contribution to diagnosis of melioidosis in a nonendemic country in three French travellers.

V Walewski1, F Méchaï2, T Billard-Pomares1, W Juguet3, F Jauréguy1, B Picard1, Y Tandjaoui-Lambiotte3, E Carbonnelle1, O Bouchaud2.   

Abstract

Melioidosis is an endemic disease in Southeast Asia and northern Australia. An increasing number of cases are being reported in nonendemic countries, making the diagnosis less obvious. We discuss the identification of Burkholderia pseudomallei using matrix-assisted desorption ionization-time of flight mass spectrometry on the occasion of recent cases of imported melioidosis in French travellers.

Entities:  

Keywords:  Burkholderia pseudomallei; MALDI-TOF MS; diagnosis; imported infectious disease; melioidosis

Year:  2016        PMID: 27222715      PMCID: PMC4872369          DOI: 10.1016/j.nmni.2016.04.004

Source DB:  PubMed          Journal:  New Microbes New Infect        ISSN: 2052-2975


Introduction

Burkholderia pseudomallei is the causative agent of melioidosis. It is common in Southeast Asia and northern Australia. In Thailand, 20% of all community-acquired cases of septicaemia are caused by B. pseudomallei, with 40% mortality. A striking rise in cases of melioidosis was observed after the December 2004 tsunami, and the disease was also more common after floods in Malaysia in 2015 (http://www.promedmail.org/direct.php?id=3218685). An augmentation of imported cases in Western countries may be strongly correlated with increased international travel (http://mkt.unwto.org/barometer) [1]. Early diagnosis of melioidosis is important considering the high mortality observed without adequate antibiotic therapy [2]. Because empirical antibiotic regimens for community-acquired pneumonia in nonendemic countries may not provide adequate treatment for melioidosis [3], [4], effective tools are needed to rapidly diagnose melioidosis.

Patients and Methods

Melioidosis was diagnosed in three French travellers in December 2013 as well as in April and August 2015 at Hôpital Avicenne, Bobigny, France. Patient characteristics are listed in Table 1. Their management and outcome were strongly related to the efficiency of the diagnosis.
Table 1

Patient characteristics

Patient No.Gender (age, years)Clinical presentation (date)Visited countryRisk factorMedical imagingLaboratory results biologyTreatment (duration)Outcome
1M (37)Fever and mild cough, rapid evolution to acute respiratory distress, multiple organ failure (December 2013)Thailand (Kho Phangan)None; tattoo?Chest x-ray revealed cavity-like lesion in upper lobe of right lung compatible with tuberculosis

Leukocytes: 22.4 × 109 L (81% neutrophils)

HBV, HCV, HIV serologies: negative

Malaria test: negative

PCT: 0.98 μg/L

Amoxicillin (7 days)

Amoxicillin-clavulanic acid (7 extra days)

Piperacillin-tazobactam + amikacin

Intravenous ceftazidime + cotrimoxazole (14 days)

Maintenance oral cotrimoxazole (6 months)

After several weeks, acute renal failure persisted along with reduced respiratory capacity.To date, no relapse observed.
2M (36)Fever, chills, alteration of general state (April 2015)Malaysia (Borneo)None; flood?Computed tomography chest scan revealed upper left lobe condensation

Leukocytes: 6.8 × 109 L (82% neutrophils)

HBV, HCV, HIV serologies: negative

Malaria test: negative

PCT: 6.8 μg/L

Intravenous ceftazidime and oral cotrimoxazole (10 days)

Maintenance oral cotrimoxazole (3 months)

Favorable clinical outcome was observed rapidly despite diagnosis of secondary prostatic abscess. To date, no relapse observed.
3F (58)Fever, chills, acute respiratory distress, diarrhoea, vomiting (August 2015)CambodiaDiabetes mellitusChest x-ray revealed alveolar condensation lesions in lower lobe of her left lung

Leukocytes: 19.6 G/L (88% neutrophils)

HIV serology: negative

PCT: 28.9 μg/L

Intravenous ceftriaxone for 24 hours; after bacterial identification, intravenous ceftazidime and oral cotrimoxazole (21 days)

Maintenance oral amoxicillin–clavulanic acid (3 months)

Clinical course was rapidly favorable. Sepsis and urinary tract infection were observed 5 months after.

HBV, hepatitis B virus; HCV, hepatitis C virus; PCT, procalcitonin.

The first patient was admitted to the emergency department with a 3-week history of community-acquired pneumonia with treatment failure. Two days after admission, marked acute respiratory distress and multiple organ failure occurred, leading to the patient's transfer to the intensive care unit for respiratory assistance and extracorporeal circulation. Concomitant with the aggravation one blood culture drawn at admission was positive Gram-negative bacilli on Gram stain. Subculture yielded Gram-negative, oxidase-positive bacilli which could not be identified using a biochemical test strip (API20E; bioMérieux, Marcy l’Étoile, France). Using molecular biology (partial sequencing of the 16S rRNA gene), B. pseudomallei was identified within 2 days. Susceptibility testing indicated a regular antimicrobial resistance pattern (Table 2).
Table 2

Antimicrobial susceptibility (disk diffusion test) of three Burkholderia pseudomallei strains

StrainAMCCAZIMPTSGmDXCL
1SSSSRSNT
2SSSSSSNT
3SSSSRSS

AMC, amoxicillin–clavulanic acid; CAZ, ceftazidime; CL, chloramphenicol; DX, doxycycline; Gm, gentamicin; IMP, imipenem; NT, not tested; R, resistant; S, sensitive; TS, trimethoprim–sulfamethoxazole (cotrimoxazole).

Patient 2 was admitted shortly after his return from Borneo. At this stage, he received no antibiotics. On day 3 of hospitalization, an aerobic blood culture drawn at admission yielded Gram-negative bacilli. Rapid identification using matrix-assisted desorption ionization–time of flight mass spectrometry (MALDI-TOF MS; Microflex LT; Bruker Daltonics, Leipzig, Germany) was performed directly on the pellet of the blood culture [5]. Within less than 1 hour, the analysis yielded Burkholderia thailandensis with a log score value of 1.83 (using the standard Bruker v4.0 database). Querying the security-relevant (SR) library, which includes bioterrorism agents (Bruker), revealed B. pseudomallei, with a log score value of >2.0. The identification was confirmed 5 days later by molecular biology (targeting genes BpSCU2 and orf11 [6]). Biochemical characterization (API20NE; bioMérieux) yielded Chromobacterium violaceum, a frequent misidentification [7]. Antimicrobial susceptibility testing by disk diffusion revealed susceptibility to compounds used in conventional treatment but an abnormal sensitivity to aminoglycosides (e.g. gentamicin) (Table 2). Patient 3 was originally a native of Cambodia; she has resided in France for 30 years but frequently returns to her home country. Culture of aerobic blood drawn at admission yielded Gram-negative bacilli. As in patient 2, the bacilli were identified within less than an hour with MALDI-TOF MS as B. pseudomallei, with a log score value >2.0 using the SR library. Antimicrobial susceptibility was identical to that of the isolate of patient 1. A relapse was observed 5 months later despite good therapy compliance.

Discussion

Underlying predisposing conditions such as diabetes mellitus have been widely described (e.g. patient 3). Patients 1 and 2 had no evident risk factors, but in patient 1, skin lesions related to a tattoo may have constituted a source of exposure [2]. There was a difference in the clinical presentation of the cases: patient 1 had a history of more than 2 weeks of inappropriate therapy, which may have led to body-wide dissemination of the pathogen, possibly explaining the severity of the clinical evolution. Culture is the reference standard for the microbiologic diagnosis of melioidosis. B. pseudomallei grows easily on standard media within 24 to 48 hours. Culture reading may be facilitated by using selective media, e.g. Ashdown medium, which is not widely used in nonendemic countries. Rapid diagnostic tools are also available in endemic countries, based on immunofluorescence, monoclonal antibodies or latex agglutination. In nonendemic countries, difficulties in identification stem from the lack of familiarity with the cultural characteristics and the nonuse of effective and specific diagnostic facilities. Above all, B. pseudomallei is usually misidentified as a culture contaminant when standard identification techniques are used (e.g. API20NE, automated Vitek) [7]. Moreover, many Malaysian strains show quite unusual biochemical characteristics and susceptibility to gentamicin, which may be misleading [7]. In the cases reported here, the microbiologic diagnosis was made in two ways. In the first case, identification of B. pseudomallei by phenotypic and molecular approaches took at least 4 days after the blood culture turned positive. In the two other cases, identification with MALDI-TOF MS gave a result the same day the blood culture turned positive. MALDI-TOF MS has been shown to be an accurate and rapid procedure for identification of B. pseudomallei if the appropriate database is used. Because this pathogen is not represented in the Main Spectra Bruker Biotyper database, the response obtained with this database is B. thailandensis, with average log score values reflecting the closeness of the two species and shared peaks in their mass spectra [8]. Identification of Burkholderia species at the genus level using the standard Bruker database should alert the microbiologist and trigger further specific characterization. Speed in the detection of B. pseudomallei in blood cultures allowed us to set up effective antibiotic therapy and protective measures without delay for laboratory workers. Indeed, precautions must be taken in manipulating this pathogen, as it is considered to be a bioterrorism agent. Cultures must be handled under biosafety level 3 laboratory conditions. Incidents of exposure of laboratory workers have been reported [1]. International travel increases the potential spread of infectious diseases, and the number of travellers to endemic areas will inexorably expand. Nonendemic countries will have to face increasing rates of imported cases that must be diagnosed rapidly using efficient procedures. Difficulties in laboratory diagnosis of melioidosis may delay adequate treatment and affect disease outcome. MALDI-TOF MS can be applied successfully to the identification of B. pseudomallei if a suitable database is used.
  8 in total

1.  Matrix-assisted laser desorption ionization-time of flight mass spectrometry for rapid identification of Burkholderia pseudomallei: importance of expanding databases with pathogens endemic to different localities.

Authors:  Susanna K P Lau; Bone S F Tang; Shirly O T Curreem; Tsz-Ming Chan; Paolo Martelli; Cindy W S Tse; Alan K L Wu; Kwok-Yung Yuen; Patrick C Y Woo
Journal:  J Clin Microbiol       Date:  2012-06-20       Impact factor: 5.948

2.  Guidelines for the management of adult lower respiratory tract infections--full version.

Authors:  M Woodhead; F Blasi; S Ewig; J Garau; G Huchon; M Ieven; A Ortqvist; T Schaberg; A Torres; G van der Heijden; R Read; T J M Verheij
Journal:  Clin Microbiol Infect       Date:  2011-11       Impact factor: 8.067

3.  Identification and discrimination of Burkholderia pseudomallei, B. mallei, and B. thailandensis by real-time PCR targeting type III secretion system genes.

Authors:  F M Thibault; E Valade; D R Vidal
Journal:  J Clin Microbiol       Date:  2004-12       Impact factor: 5.948

4.  Infectious Diseases Society of America/American Thoracic Society consensus guidelines on the management of community-acquired pneumonia in adults.

Authors:  Lionel A Mandell; Richard G Wunderink; Antonio Anzueto; John G Bartlett; G Douglas Campbell; Nathan C Dean; Scott F Dowell; Thomas M File; Daniel M Musher; Michael S Niederman; Antonio Torres; Cynthia G Whitney
Journal:  Clin Infect Dis       Date:  2007-03-01       Impact factor: 9.079

Review 5.  Melioidosis.

Authors:  W Joost Wiersinga; Bart J Currie; Sharon J Peacock
Journal:  N Engl J Med       Date:  2012-09-13       Impact factor: 91.245

6.  Real-time identification of bacteria and Candida species in positive blood culture broths by matrix-assisted laser desorption ionization-time of flight mass spectrometry.

Authors:  Agnès Ferroni; Stéphanie Suarez; Jean-Luc Beretti; Brunhilde Dauphin; Emmanuelle Bille; Julie Meyer; Marie-Elisabeth Bougnoux; Alexandre Alanio; Patrick Berche; Xavier Nassif
Journal:  J Clin Microbiol       Date:  2010-03-17       Impact factor: 5.948

7.  Melioidosis Cases and Selected Reports of Occupational Exposures to Burkholderia pseudomallei--United States, 2008-2013.

Authors:  Tina J Benoit; David D Blaney; Jay E Gee; Mindy G Elrod; Alex R Hoffmaster; Thomas J Doker; William A Bower; Henry T Walke
Journal:  MMWR Surveill Summ       Date:  2015-07-03

8.  Melioidosis diagnostic workshop, 2013.

Authors:  Alex R Hoffmaster; David AuCoin; Prasith Baccam; Henry C Baggett; Rob Baird; Saithip Bhengsri; David D Blaney; Paul J Brett; Timothy J G Brooks; Katherine A Brown; Narisara Chantratita; Allen C Cheng; David A B Dance; Saskia Decuypere; Dawn Defenbaugh; Jay E Gee; Raymond Houghton; Possawat Jorakate; Ganjana Lertmemongkolchai; Direk Limmathurotsakul; Toby L Merlin; Chiranjay Mukhopadhyay; Robert Norton; Sharon J Peacock; Dionne B Rolim; Andrew J Simpson; Ivo Steinmetz; Robyn A Stoddard; Martha M Stokes; David Sue; Apichai Tuanyok; Toni Whistler; Vanaporn Wuthiekanun; Henry T Walke
Journal:  Emerg Infect Dis       Date:  2015-02       Impact factor: 6.883

  8 in total
  7 in total

Review 1.  Human Melioidosis.

Authors:  I Gassiep; M Armstrong; R Norton
Journal:  Clin Microbiol Rev       Date:  2020-03-11       Impact factor: 26.132

2.  Identification of Burkholderia pseudomallei by Use of the Vitek Mass Spectrometer.

Authors:  I Gassiep; M Armstrong; R E Norton
Journal:  J Clin Microbiol       Date:  2019-04-26       Impact factor: 5.948

3.  The Brief Case: A Traveler's Tale-Burkholderia pseudomallei Infection in a Cystic Fibrosis Patient.

Authors:  I T Hettiarachchi; J Duckers; D Lau; R Dhillon
Journal:  J Clin Microbiol       Date:  2019-11-22       Impact factor: 5.948

4.  Misidentification of Risk Group 3/Security Sensitive Biological Agents by MALDI-TOF MS in Canada: November 2015-October 2017.

Authors:  D Pomerleau-Normandin; M Heisz; M Su
Journal:  Can Commun Dis Rep       Date:  2018-05-03

5.  Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for the identification of Burkholderia pseudomallei from Asia and Australia and differentiation between Burkholderia species.

Authors:  Vichaya Suttisunhakul; Apinya Pumpuang; Peeraya Ekchariyawat; Vanaporn Wuthiekanun; Mindy G Elrod; Paul Turner; Bart J Currie; Rattanaphone Phetsouvanh; David A B Dance; Direk Limmathurotsakul; Sharon J Peacock; Narisara Chantratita
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

6.  Antibodies in Melioidosis: The Role of the Indirect Hemagglutination Assay in Evaluating Patients and Exposed Populations.

Authors:  Panjaporn Chaichana; Kemajittra Jenjaroen; Premjit Amornchai; Suchintana Chumseng; Sayan Langla; Patpong Rongkard; Manutsanun Sumonwiriya; Atthanee Jeeyapant; Narisara Chantratita; Prapit Teparrukkul; Direk Limmathurotsakul; Nicholas P J Day; Vanaporn Wuthiekanun; Susanna J Dunachie
Journal:  Am J Trop Med Hyg       Date:  2018-12       Impact factor: 2.345

7.  A multi-country study using MALDI-TOF mass spectrometry for rapid identification of Burkholderia pseudomallei.

Authors:  Wanitda Watthanaworawit; Tamalee Roberts; Jill Hopkins; Ian Gassiep; Robert Norton; Matthew T Robinson; Joy Silisouk; Poda Sar; Sena Sao; Premjit Amornchai; Direk Limmathurotsakul; Vanaporn Wuthiekanun; Francois Nosten; Andrew J H Simpson; Paul Turner; Clare L Ling
Journal:  BMC Microbiol       Date:  2021-07-16       Impact factor: 3.605

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.